{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"1"}],"units":"Participants"}],"description":"DLT was defined as any of the following adverse events occurring in the first cycle of treatment (21 days after the first dose): a) Hematologic: Febrile neutropenia defined as an absolute neutrophil count (ANC) \\<1.0 x 10\\^9/L with a single temperature of \\>38.3°C, or 101°F, or a sustained temperature of \\>=38°C, or 100.4°F, for more than one hour; b) Non-hematologic: Delay by more than 2 weeks in receiving the next scheduled dose due to persisting treatment related toxicities; c) Any grade 3 or 4 clinically-relevant hematologic or non-hematologic toxicity.","groups":[{"description":"PF-06671008 was administered as a weekly intravenous (IV) infusion in 21-day cycles at 1.5 ng/kg. PF-06671008 was administered for up to 4 cycles in this cohort.","id":"OG000","title":"PF-06671008 1.5 ng/kg IV"},{"description":"PF-06671008 was administered as a weekly IV infusion in 21-day cycles at 7.5 ng/kg. PF-06671008 was administered for up to 3 cycles in this cohort.","id":"OG001","title":"PF-06671008 7.5 ng/kg IV"},{"description":"PF-06671008 was administered as a weekly IV infusion in 21-day cycles at 20 ng/kg. PF-06671008 was administered for up to 4 cycles in this cohort.","id":"OG002","title":"PF-06671008 20 ng/kg IV"},{"description":"PF-06671008 was administered as a weekly IV infusion in 21-day cycles at 50 ng/kg. PF-06671008 was administered for up to 2 cycles in this cohort.","id":"OG003","title":"PF-06671008 50 ng/kg IV"},{"description":"PF-06671008 was administered as a weekly IV infusion in 21-day cycles at 100 ng/kg. PF-06671008 was administered for up to 4 cycles in this cohort.","id":"OG004","title":"PF-06671008 100 ng/kg IV"},{"description":"PF-06671008 was administered as a weekly IV infusion in 21-day cycles at 200 ng/kg. PF-06671008 was administered for up to 16 cycles in this cohort.","id":"OG005","title":"PF-06671008 200 ng/kg IV"},{"description":"PF-06671008 was administered as a weekly IV infusion in 21-day cycles at 300 ng/kg. PF-06671008 was administered for up to 4 cycles in this cohort.","id":"OG006","title":"PF-06671008 300 ng/kg IV"},{"description":"PF-06671008 was administered as a weekly IV infusion in 21-day cycles at 400 ng/kg. PF-06671008 was administered for up to 2 cycles in this cohort.","id":"OG007","title":"PF-06671008 400 ng/kg IV"},{"description":"PF-06671008 was administered as a weekly subcutaneous (SC) injection in 21-day cycles at 200 ng/kg. PF-06671008 was administered for up to 5 cycles in this cohort.","id":"OG008","title":"PF-06671008 200 ng/kg SC"},{"description":"PF-06671008 was administered as a weekly IV infusion in 21-day cycles at a priming dose of 200 ng/kg on Cycle 1 Day 1 (C1D1) and 300 ng/kg for all subsequent dosing. PF-06671008 was administered for up to 4 cycles in this cohort.","id":"OG009","title":"PF-06671008 200 ng/kg Prime and 300 ng/kg Maintenance IV"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All enrolled participants who received at least one dose of study intervention.","reportingStatus":"POSTED","timeFrame":"Baseline through Day 21 (Cycle 1)","title":"Number of Participants With Dose-Limiting Toxicities (DLTs) - Part 1","type":"PRIMARY","unitOfMeasure":"Participants"}